home / stock / arfxf / arfxf news

ARFXF News and Press, Amorfix Life Sciences Ltd From 05/20/20

Stock Information
Company Name: Amorfix Life Sciences Ltd
Stock Symbol: ARFXF
Market: OTC
Website: promisneurosciences.com
Menu
ARFXF ARFXF Quote ARFXF Short ARFXF News ARFXF Articles ARFXF Message Board
Get ARFXF Alerts

News, Short Squeeze, Breakout and More Instantly...
ARFXF - ProMIS Neurosciences Chairman's Update details new programs from expanded use of novel technology platform

TORONTO and CAMBRIDGE, Mass., May 20, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative disease...
ARFXF - ProMIS Neurosciences and BC Neuroimmunology expand collaboration to develop and commercialize proprietary diagnostic assays

TORONTO and CAMBRIDGE, Mass., May 19, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a company with unique, core technology to predict novel targets on the molecular surface of complex proteins, announced today that, in addition to its ongoing program to deve...

ARFXF - ProMIS Neurosciences Announces First Quarter 2020 Results

TORONTO and CAMBRIDGE, Mass., May 13, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS or the Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the ...

ARFXF - ProMIS Neurosciences identifies multiple novel targets on SARS CoV-2 for development of a highly accurate COVID-19 antibody test

TORONTO, Ontario and CAMBRIDGE, Mass., May 12, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a company with unique, core technology to predict novel targets on the molecular surface of complex proteins, has advanced its program to develop a high-throughput, ...
ARFXF - ProMIS Neurosciences develops novel antagonists for RACK1, a protein involved in numerous neurodegenerative diseases, including ALS

TORONTO and CAMBRIDGE, Mass., May 06, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative disease...

ARFXF - ProMIS up 11% new antibodies for neurodegenerative diseases

Thinly traded nano cap ProMIS Neurosciences ( OTCQB:ARFXF +10.5% ) is up on 65% higher volume in reaction to its announcement that it has produced intrabodies that are "highly selective" for misfolded forms of a protein called TDP-43 that is implicated in amyotrophic lateral sclerosis (A...

ARFXF - ProMIS Neurosciences creates novel intrabodies for ALS, frontotemporal dementia and other neurodegenerative diseases

TORONTO and CAMBRIDGE, Mass., April 30, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative disea...
ARFXF - ProMIS Neurosciences commends Biogen for clarifying aducanumab regulatory filing

Ongoing rolling BLA submission to the FDA supports completion by Q3;  ProMIS applauds advancement in profoundly challenging environment TORONTO and CAMBRIDGE, Mass., April 22, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company fo...

ARFXF - ProMIS Neurosciences announces collaboration to develop serological test to assess COVID-19 immunity

TORONTO and CAMBRIDGE, Mass., April 15, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a company with a unique, core technology to predict novel targets on the molecular surface of complex proteins, announced today a collaboration with Dr. Hans Frykman and hi...

ARFXF - Journal of the American Academy of Neurology Publishes ProMIS Neurosciences' Abstracts on Novel Antibody Candidates

TORONTO and CAMBRIDGE, Mass., April 09, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers of proteins implicated in the development of neurodegene...
Previous 10 Next 10